Alkermes, Inc.

This study looks at the long-term safety and how well ALKS 2680 works for people with narcolepsy type 1, type 2, or idiopathic hypersomnia. About 256 adults who finished a previous ALKS 2680 study will take the tablet and be monitored for side effects and improvements in daytime …

This study compares a new drug combination (OLZ/SAM) to the standard drug olanzapine in teenagers with schizophrenia or bipolar I disorder. The main goal is to see if OLZ/SAM causes less weight gain over 12 weeks. About 220 teens aged 10-17 will take either OLZ/SAM or olanzapine …

This study tests an experimental tablet called ALKS 2680 in 150 adults with narcolepsy type 1, a condition causing severe daytime sleepiness and sudden muscle weakness (cataplexy). Participants receive either the drug or a placebo for 12 weeks. The goal is to see if the drug help…

This study tests a new drug, ALKS 2680, to see if it safely reduces excessive daytime sleepiness in people with idiopathic hypersomnia, a condition causing severe sleepiness without clear cause. About 96 adults will take either the drug or a placebo for 8 weeks. The main goal is …

This study tests a new medication called ALKS 2680 to see if it can reduce daytime sleepiness and other symptoms in adults with narcolepsy type 2. About 176 participants will receive either the study drug or a placebo pill. The main goal is to measure how well they can stay awake…